Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Cash (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Cash for 4 consecutive years, with $6.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash fell 97.55% to $6.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$344.2 million, a 253.99% decrease, with the full-year FY2024 number at $255.2 million, up 196.08% from a year prior.
  • Change in Cash was $6.6 million for Q3 2025 at Centessa Pharmaceuticals, up from -$60.9 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $267.7 million in Q3 2024 to a low of -$278.1 million in Q1 2025.
  • A 4-year average of -$36.3 million and a median of -$43.5 million in 2023 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: surged 918.55% in 2024, then crashed 2733.93% in 2025.
  • Centessa Pharmaceuticals' Change in Cash stood at -$51.2 million in 2022, then grew by 15.1% to -$43.5 million in 2023, then skyrocketed by 72.84% to -$11.8 million in 2024, then skyrocketed by 155.65% to $6.6 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Cash are $6.6 million (Q3 2025), -$60.9 million (Q2 2025), and -$278.1 million (Q1 2025).